BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 32965016)

  • 21. Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?
    Thalha AMM; Lee YY; Besari A; Omar SFS
    J R Coll Physicians Edinb; 2020 Jun; 50(2):159-161. PubMed ID: 32568289
    [No Abstract]   [Full Text] [Related]  

  • 22. Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.
    Banerjee AK; Arora N
    Curr Top Med Chem; 2020; 20(16):1434-1437. PubMed ID: 32282303
    [No Abstract]   [Full Text] [Related]  

  • 23. COVID-19: Underlying Adipokine Storm and Angiotensin 1-7 Umbrella.
    Méry G; Epaulard O; Borel AL; Toussaint B; Le Gouellec A
    Front Immunol; 2020; 11():1714. PubMed ID: 32793244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
    Tu YF; Chien CS; Yarmishyn AA; Lin YY; Luo YH; Lin YT; Lai WY; Yang DM; Chou SJ; Yang YP; Wang ML; Chiou SH
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection.
    Goyal RK; Majeed J; Tonk R; Dhobi M; Patel B; Sharma K; Apparsundaram S
    Rev Cardiovasc Med; 2020 Sep; 21(3):365-384. PubMed ID: 33070542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
    Williamson BN; Feldmann F; Schwarz B; Meade-White K; Porter DP; Schulz J; van Doremalen N; Leighton I; Yinda CK; Pérez-Pérez L; Okumura A; Lovaglio J; Hanley PW; Saturday G; Bosio CM; Anzick S; Barbian K; Cihlar T; Martens C; Scott DP; Munster VJ; de Wit E
    Nature; 2020 Sep; 585(7824):273-276. PubMed ID: 32516797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Audio Interview: New Data on Remdesivir in Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 May; 382(22):e94. PubMed ID: 32459948
    [No Abstract]   [Full Text] [Related]  

  • 28. The viral, epidemiologic, clinical characteristics and potential therapy options for COVID-19: a review.
    Li C; Xu BH
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4576-4584. PubMed ID: 32373998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in children.
    Miao H; Li H; Yao Y; Wu M; Lu C; Wang J; Tian M; Li Y; Luo P; Gu J; Yuan B; Wang S; Zhao X; Gan W; Zhao D
    Eur J Clin Microbiol Infect Dis; 2020 Dec; 39(12):2211-2223. PubMed ID: 32761481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 and COVID-19: How much do we know?
    Wang M; Liao Z
    Acta Virol; 2020; 64(3):288-296. PubMed ID: 32985201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2).
    Maveddat A; Mallah H; Rao S; Ali K; Sherali S; Nugent K
    Int J Occup Environ Med; 2020 Oct; 11(4):157-178. PubMed ID: 33098401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coronavirus Disease 2019: Clinical Review.
    Gouveia CC; Campos L
    Acta Med Port; 2020 Jul; 33(7-8):505-511. PubMed ID: 32498762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.
    Ballout RA; Sviridov D; Bukrinsky MI; Remaley AT
    FASEB J; 2020 Jun; 34(6):7253-7264. PubMed ID: 32367579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2: characteristics and current advances in research.
    Yang Y; Xiao Z; Ye K; He X; Sun B; Qin Z; Yu J; Yao J; Wu Q; Bao Z; Zhao W
    Virol J; 2020 Jul; 17(1):117. PubMed ID: 32727485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.
    Prete M; Favoino E; Catacchio G; Racanelli V; Perosa F
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic.
    Kouzy R; Abi Jaoude J; Garcia Garcia CJ; El Alam MB; Taniguchi CM; Ludmir EB
    JAMA Netw Open; 2020 Jul; 3(7):e2015100. PubMed ID: 32658285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic~Strategies.
    Samidurai A; Das A
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32947927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Lai CC; Liu YH; Wang CY; Wang YH; Hsueh SC; Yen MY; Ko WC; Hsueh PR
    J Microbiol Immunol Infect; 2020 Jun; 53(3):404-412. PubMed ID: 32173241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stem Cell Transplantation Therapy: A Potential Method for Treating Cytokine Storm Syndromes Induced by COVID-19.
    Wang HC; Wang X; Long X
    Cell Transplant; 2020; 29():963689720965980. PubMed ID: 33040594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease.
    Rodriguez Z; Shane AL; Verkerke H; Lough C; Zimmerman MG; Suthar M; Wrammert J; MacDonald H; Wolf M; Clarke S; Roback JD; Arthur CM; Stowell SR; Josephson CD
    Blood Adv; 2020 Sep; 4(18):4278-4281. PubMed ID: 32915971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.